These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 31383252)

  • 41. LRRK2 regulates synaptic vesicle endocytosis.
    Shin N; Jeong H; Kwon J; Heo HY; Kwon JJ; Yun HJ; Kim CH; Han BS; Tong Y; Shen J; Hatano T; Hattori N; Kim KS; Chang S; Seol W
    Exp Cell Res; 2008 Jun; 314(10):2055-65. PubMed ID: 18445495
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Parkinson's Disease: A Traffic Jam?
    Clague MJ; Rochin L
    Curr Biol; 2016 Apr; 26(8):R332-4. PubMed ID: 27115692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
    Daniëls V; Baekelandt V; Taymans JM
    Neurosignals; 2011; 19(1):1-15. PubMed ID: 21430363
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium.
    Guttuso T; Andrzejewski KL; Lichter DG; Andersen JK
    J Neurol Sci; 2019 Jul; 402():121-130. PubMed ID: 31129265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
    Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
    Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
    [TBL] [Abstract][Full Text] [Related]  

  • 46. LRRK2 and Parkinson's disease: from genetics to targeted therapy.
    Sosero YL; Gan-Or Z
    Ann Clin Transl Neurol; 2023 Jun; 10(6):850-864. PubMed ID: 37021623
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Presynaptic dysfunction in Parkinson's disease: a focus on LRRK2.
    Belluzzi E; Greggio E; Piccoli G
    Biochem Soc Trans; 2012 Oct; 40(5):1111-6. PubMed ID: 22988874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
    Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
    Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.
    Blanca Ramírez M; Lara Ordóñez AJ; Fdez E; Madero-Pérez J; Gonnelli A; Drouyer M; Chartier-Harlin MC; Taymans JM; Bubacco L; Greggio E; Hilfiker S
    Hum Mol Genet; 2017 Jul; 26(14):2747-2767. PubMed ID: 28453723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
    Nguyen AP; Moore DJ
    Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
    Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting leucine-rich repeat kinase 2 in Parkinson's disease.
    Chan SL; Angeles DC; Tan EK
    Expert Opin Ther Targets; 2013 Dec; 17(12):1471-82. PubMed ID: 24206363
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain.
    Piccoli G; Onofri F; Cirnaru MD; Kaiser CJ; Jagtap P; Kastenmüller A; Pischedda F; Marte A; von Zweydorf F; Vogt A; Giesert F; Pan L; Antonucci F; Kiel C; Zhang M; Weinkauf S; Sattler M; Sala C; Matteoli M; Ueffing M; Gloeckner CJ
    Mol Cell Biol; 2014 Jun; 34(12):2147-61. PubMed ID: 24687852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulation of LRRK2: insights from structural and biochemical analysis.
    Gilsbach BK; Eckert M; Gloeckner CJ
    Biol Chem; 2018 Jun; 399(7):637-642. PubMed ID: 29894291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function.
    Blanca Ramírez M; Madero-Perez J; Rivero-Rios P; Martinez-Salvador M; Lara Ordonez AJ; Fernandez B; Fdez E; Hilfiker S
    Curr Protein Pept Sci; 2017; 18(7):677-686. PubMed ID: 26965688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The LRRK2-RAB axis in regulation of vesicle trafficking and α-synuclein propagation.
    Bae EJ; Lee SJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165632. PubMed ID: 31812666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional and behavioral consequences of Parkinson's disease-associated
    Benson DL; Matikainen-Ankney BA; Hussein A; Huntley GW
    Biochem Soc Trans; 2018 Dec; 46(6):1697-1705. PubMed ID: 30514770
    [No Abstract]   [Full Text] [Related]  

  • 58. Cross-talk between LRRK2 and PKA: implication for Parkinson's disease?
    Greggio E; Bubacco L; Russo I
    Biochem Soc Trans; 2017 Feb; 45(1):261-267. PubMed ID: 28202680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.
    Azeggagh S; Berwick DC
    Br J Pharmacol; 2022 Apr; 179(8):1478-1495. PubMed ID: 34050929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LRRK2 Phosphorylation.
    Nichols RJ
    Adv Neurobiol; 2017; 14():51-70. PubMed ID: 28353278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.